Lakefront Biotherapeutics (GLPGF) EBIT Margin (2014 - 2026)
Lakefront Biotherapeutics' (GLPGF) quarterly EBIT Margin came in at 358.92% in Q2 2026, down 27167.0% year-over-year from N/an in Q2 2025, and up 63.48% quarter-over-quarter from 982.92% in Q1 2026.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EBIT Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported EBIT Margin for 13 consecutive years, with 358.92% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBIT Margin fell 27167.0% year-over-year to 358.92% in Q2 2026; TTM through Jun 2026 was 40.59%, a 13965.0% increase from a year earlier, with the FY2025 full-year figure at 26.53%, up 9485.0% from the prior year.
- EBIT Margin was 358.92% for Q2 2026 at Lakefront Biotherapeutics, up from 982.92% in the prior quarter.
- Over five years, EBIT Margin peaked at 190.13% in Q4 2024 and troughed at 982.92% in Q1 2026.
- A 5-year average of 134.43% and a median of 40.32% in 2024 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin soared 31641 bps in 2025 and sank 77124 bps in 2026, its largest moves.
- Over 5 years, EBIT Margin stood at 2.37% in 2022, then jumped by 1787 bps to 39.96% in 2023, then soared by 376 bps to 190.13% in 2024, then tumbled by 56 bps to 84.06% in 2025, then slumped by 527 bps to 358.92% in 2026.
- The last three EBIT Margin figures came in at 358.92% (Q2 2026), 982.92% (Q1 2026), and 84.06% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | -25,380.93% |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -358.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -358.92% |
| Mar 31, 2026 | -982.92% |
| Dec 31, 2025 | 84.06% |
| Sep 30, 2025 | -346.51% |
| Jun 30, 2025 | -87.25% |
| Mar 31, 2025 | -211.68% |
| Dec 31, 2024 | 190.13% |
| Sep 30, 2024 | -119.07% |
| Jun 30, 2024 | -403.65% |
| Mar 31, 2024 | -53.07% |
| Dec 31, 2023 | 39.96% |
| Sep 30, 2023 | -23.23% |
| Jun 30, 2023 | -22.49% |
| Mar 31, 2023 | -24.24% |
| Dec 31, 2022 | -2.37% |
| Sep 30, 2022 | -27.58% |
| Jun 30, 2022 | -55.47% |
| Mar 31, 2022 | -15.51% |
| Dec 31, 2021 | -4.95% |
| Sep 30, 2021 | -55.27% |